These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29926158)

  • 1. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.
    Haghpanah S; Zarei T; Eshghi P; Zekavat O; Bordbar M; Hoormand M; Karimi M
    Ann Hematol; 2018 Oct; 97(10):1919-1924. PubMed ID: 29926158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
    El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
    Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.
    Ren Q; Zhou YL; Wang L; Chen YS; Ma YN; Li PP; Yin XL
    Ann Hematol; 2018 Oct; 97(10):1933-1939. PubMed ID: 29931453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
    Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
    Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
    Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
    Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia.
    Karimi M; Mohammadi F; Behmanesh F; Samani SM; Borzouee M; Amoozgar H; Haghpanah S
    Eur J Haematol; 2010 Jan; 84(1):52-8. PubMed ID: 19799627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of exercise training with resveratrol supplementation on skeletal muscle mitochondrial capacity.
    Polley KR; Jenkins N; O'Connor P; McCully K
    Appl Physiol Nutr Metab; 2016 Jan; 41(1):26-32. PubMed ID: 26638911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
    Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
    Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical observation on YiSuiShengXueGranule on treating 156 patients with beta-thalassemia major and the molecular mechanism study.
    Fang S; Wu Z; Zhang X; Liu Y; Wang W; Chai L; Cai H; Yi J; Wang L; Chen Y; Lv X; Huang Y; Wang R; Chen P
    Biol Pharm Bull; 2007 Nov; 30(11):2084-7. PubMed ID: 17978480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
    Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
    Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
    Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
    Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
    Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
    Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
    Kosaryan M; Karami H; Zafari M; Yaghobi N
    Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea in the management of thalassemia intermedia.
    Karimi M
    Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
    Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
    Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.